Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Involvement of Spinal CB1 Cannabinoid Receptors on the Antinociceptive Effect of Celecoxib in Rat Formalin Test

Mohsen Rezaei 1 , Hossein Rajabi Vardanjani 2 , Marzieh Pashmforoosh 2 , Davood Alipour 2 , Ali Nesari 2 , Zahra Mansourzade 3 and Mohammad Javad Khodayar 2 , 3 , *
Authors Information
1 Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
2 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: August 01, 2016, 11 (3); e33433
  • Published Online: March 16, 2016
  • Article Type: Research Article
  • Received: September 28, 2015
  • Revised: February 14, 2016
  • Accepted: February 24, 2016
  • DOI: 10.17795/jjnpp-33433

To Cite: Rezaei M, Rajabi Vardanjani H, Pashmforoosh M, Alipour D, Nesari A, et al. Involvement of Spinal CB1 Cannabinoid Receptors on the Antinociceptive Effect of Celecoxib in Rat Formalin Test, Jundishapur J Nat Pharm Prod. 2016 ; 11(3):e33433. doi: 10.17795/jjnpp-33433.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005; 107(2): 139-54[DOI][PubMed]
  • 2. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996; 52 Suppl 5: 13-23[PubMed]
  • 3. Khanna IK, Weier RM, Yu Y, Xu XD, Koszyk FJ, Collins PW, et al. 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. J Med Chem. 1997; 40(11): 1634-47[DOI][PubMed]
  • 4. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000; 47(2): 123-8[DOI]
  • 5. Zhao FY, Spanswick D, Martindale JC, Reeve AJ, Chessell IP. GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. Pain. 2007; 128(1-2): 78-87[DOI][PubMed]
  • 6. Rezende RM, Paiva-Lima P, Dos Reis WG, Camelo VM, Faraco A, Bakhle YS, et al. Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. Pharmacology. 2012; 89(3-4): 127-36[DOI][PubMed]
  • 7. Rezende RM, Dos Reis WG, Duarte ID, Lima PP, Bakhle YS, de Francischi JN. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain. 2009; 142(1-2): 94-100[DOI][PubMed]
  • 8. Correa JD, Paiva-Lima P, Rezende RM, Dos Reis WG, Ferreira-Alves DL, Bakhle YS, et al. Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci. 2010; 86(25-26): 951-6[DOI][PubMed]
  • 9. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008; 153(2): 319-34[DOI][PubMed]
  • 10. Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, Hohmann AG. Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain. 2011; 152(9): 1976-87[DOI][PubMed]
  • 11. Karlsson J, Fowler CJ. Inhibition of endocannabinoid metabolism by the metabolites of ibuprofen and flurbiprofen. PLoS One. 2014; 9(7)[DOI][PubMed]
  • 12. Fowler CJ. NSAIDs: eNdocannabinoid stimulating anti-inflammatory drugs? Trends Pharmacol Sci. 2012; 33(9): 468-73[DOI][PubMed]
  • 13. Guindon J, LoVerme J, De Lean A, Piomelli D, Beaulieu P. Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol. 2006; 550(1-3): 68-77[DOI][PubMed]
  • 14. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983; 16(2): 109-10[DOI]
  • 15. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav. 1976; 17(6): 1031-6[PubMed]
  • 16. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977; 4(2): 161-74[PubMed]
  • 17. Adibpour N, Poornajjari A, Khodayar MJ, Rezaee S. Antinociceptive effect of some biuret derivatives on formalin test in mice. Adv Pharm Bull. 2014; 4(2): 179-83[DOI][PubMed]
  • 18. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992; 257(5074): 1276-9[PubMed]
  • 19. McMahon S, Koltzenburg M, Tracey I, Turk DC. Wall and Melzack's Textbook of Pain. 2013;
  • 20. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998; 345(2): 145-53[DOI]
  • 21. Fowler CJ, Stenstrom A, Tiger G. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Pharmacol Toxicol. 1997; 80(2): 103-7[DOI]
  • 22. Gühring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, et al. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol. 2002; 454(2): 153-63[DOI]
  • 23. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Guhring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci. 2003; 17(3): 597-604[PubMed]
  • 24. Seidel K, Hamza M, Ates M, Gühring H. Flurbiprofen inhibits capsaicin induced calcitonin gene related peptide release from rat spinal cord via an endocannabinoid dependent mechanism. Neurosci Lett. 2003; 338(2): 99-102[DOI]
  • 25. Fowler CJ, Janson U, Johnson RM, Wahlstrom G, Stenstrom A, Norstrom K, et al. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch Biochem Biophys. 1999; 362(2): 191-6[PubMed]
  • 26. Franca DS, Ferreira-Alves DL, Duarte ID, Ribeiro MC, Rezende RM, Bakhle YS, et al. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology. 2006; 51(1): 37-43[DOI][PubMed]
  • 27. Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol. 2002; 137(6): 837-44[DOI][PubMed]
  • 28. Lu ZH, Xiong XY, Zhang BL, Lin GC, Shi YX, Liu ZG, et al. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin. 2005; 26(12): 1505-11[DOI][PubMed]
  • 29. Nishiyama T. Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats. Acta Anaesthesiol Scand. 2006; 50(2): 228-33[DOI][PubMed]
  • 30. Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg. 2002; 94(4): 962-7[PubMed]
  • 31. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002; (68): 619-31[DOI]
  • 32. Bagues A, Martin MI, Sanchez-Robles EM. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Eur J Pharmacol. 2014; 745: 69-75[DOI][PubMed]
  • 33. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006; 46: 101-22[DOI][PubMed]
  • 34. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2004; 5(4): 430-5[PubMed]
  • 35. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 1998; 813(2): 323-8[DOI]
  • 36. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol. 1997; 319(2-3)-4[PubMed]
  • 37. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 1998; 18(1): 451-7[PubMed]
  • 38. Naderi N, Shafaghi B, Khodayar MJ, Zarindast MR. Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat. Eur J Pharmacol. 2005; 514(2-3): 159-64[DOI][PubMed]
  • 39. Telleria-Diaz A, Schmidt M, Kreusch S, Neubert AK, Schache F, Vazquez E, et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain. 2010; 148(1): 26-35[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments